NIH Seeks Comments on Chimpanzee Research Tracking Form
Published Date: 6/23/2026
Notice
Summary
The NIH wants to keep collecting info using the Chimpanzee Research Use Form and is asking the public to share thoughts by July 23, 2026. This form helps track how chimpanzees are used in research, affecting scientists and animal welfare groups. No big changes or costs are expected, just a smooth extension of the current form’s approval.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Funding Limited to Noninvasive Chimpanzee Research
The NIH will not fund research involving chimpanzees in new or competing projects unless the proposed work meets the definition of "noninvasive research" in the Standards of Care (42 CFR part 9). Proposals that do not meet that definition will not receive NIH funding.
Mandatory Chimpanzee Form for Funding
If you propose noninvasive research involving chimpanzees and want NIH support or approval, you must complete the Chimpanzee Research Use Form. The NIH will review the form before making funding decisions or allowing the research to begin.
Estimated Time Burden for Respondents
NIH estimates no monetary costs to respondents other than time: 30 respondents will each spend about 30 minutes per response, for a total estimated annualized burden of 15 hours. OMB approval is being requested for three years and the current control expires 7/31/2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
Previous / Next Documents
Previous: 2026-12584, Civil Service Retirement System; Present Value Factors
The Office of Personnel Management is updating the math used to figure certain Civil Service Retirement benefits starting October 1, 2026. This affects retirees who choose survivor benefits after marriage, owe redeposits, or fix retirement coverage errors. These changes make sure benefits stay fair and match new economic and life expectancy info.
Next: 2026-12586, Agency Information Collection Activities; Proposed Collection; Comment Request; Extension: Rule 19b-7 and Form 19b-7
The SEC is asking for comments to keep using Rule 19b-7 and Form 19b-7, which help certain stock and futures trading groups update their rules smoothly. This affects self-regulatory organizations that oversee trading in security futures products. No big changes or costs are expected, but the SEC wants to make sure everything stays clear and up-to-date.